HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naive Noncirrhotic Patients With HCV Genotype 1.

ABSTRACT:

Background

The efficacy of licensed direct-acting antiviral (DAA) regimens is assumed to be the same for hepatitis C virus (HCV)-monoinfected patients (HCV-Mono) and HIV/HCV-coinfected patients (HCV-Co). However, the high sustained viral response (SVR) rates of DAA regimens and the small number of HIV-infected patients included in registration trials have made it difficult to identify predictors of treatment failure, including the presence of HIV.

Methods

We compared treatment outcomes for ledipasvir/sofosbuvir (LDV/SOF) against HCV G1 in treatment-naïve HCV-Mono and HCV-Co without cirrhosis in a prospective registry of individuals receiving DAAs for HCV.

Results

Up to September 2017, a total of 17 269 patients were registered, and 1358 patients (1055 HCV-Mono/303 HCV

SUBMITTER: Berenguer J 

PROVIDER: S-EPMC6534283 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature